Orthocell (ASX: OCC) Lines Up UK Distributor for Remplir Ahead of Approval- Is Now the Time to Buy?

Orthocell Moves Closer to UK Growth Orthocell (ASX: OCC) just made a move that not every small-cap medtech company would make. Rather than waiting for regulatory approval before signing a…

ByUjjwal Maheshwari

24

Jan 2026

Healthcare Stocks

Aroa Biosurgery (ASX: ARX): Why This Newly Profitable Medtech Looks Like a Buy at Current Levels

Aroa Biosurgery adds new trauma study as profits turn positive Aroa Biosurgery (ASX: ARX) shares have seen increased activity this week, hovering around the A$0.70 level following news that…

ByUjjwal Maheshwari

22

Jan 2026

Healthcare Stocks

Anteris Technologies (ASX: AVR) Surges 30% on Medtronic Deal- Is It a Buy?

Anteris Technologies Gains Momentum with Medtronic Partnership Anteris Technologies (ASX: AVR) jumped more than 30% after announcing a deal that could change its future. The Australian heart valve company secured…

ByUjjwal Maheshwari

Orthocell (ASX: OCC) Lines Up UK Distributor for Remplir Ahead of Approval- Is Now the Time to Buy?

Aroa Biosurgery (ASX: ARX): Why This Newly Profitable Medtech Looks Like a Buy at Current Levels

Anteris Technologies (ASX: AVR) Surges 30% on Medtronic Deal- Is It a Buy?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Orthocell (ASX: OCC) Lines Up UK Distributor for Remplir Ahead of Approval- Is Now the Time to Buy?

Aroa Biosurgery (ASX: ARX): Why This Newly Profitable Medtech Looks Like a Buy at Current Levels

Anteris Technologies (ASX: AVR) Surges 30% on Medtronic Deal- Is It a Buy?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here